EMA Application withdrawn: Apremilast Viatris (apremilast) — Viatris Limited

View source ↗

Summary

The European Medicines Agency has withdrawn Viatris Limited's application for apremilast (Viatris) for the EU market, terminating the marketing authorization pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behçet Syndrome
• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Status: Application withdrawn. Therapeutic area: Arthritis, Psoriatic;Psoriasis;Behcet Syndrome. MAH: Viatris Limited